» Articles » PMID: 23148540

Nanodelivery Strategies in Cancer Chemotherapy: Biological Rationale and Pharmaceutical Perspectives

Overview
Specialty Biotechnology
Date 2012 Nov 15
PMID 23148540
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Nanotechnology is revolutionizing our approach to drug delivery, a key determinant of drug efficacy. Here, we present cancer drug delivery strategies that exploit nanotechnology, providing first an overview of tumor biology aspects that critically affect the design of drug delivery carriers, namely the enhanced permeability and retention effect, the lower tumor extracellular pH and tumor-specific antigens. In general, nanoscience-based approaches have circumvented limitations in the delivery of cancer therapeutics, related to their poor aqueous solubility and toxicity issues with conventional vehicles and resulted in improved pharmacokinetics and biodistribution. Included in the discussion are promising examples and pharmaceutical perspectives on liposomes, nanoemulsions, solid lipid nanoparticles, polymeric nanoparticles, dendrimers, carbon nanotubes and magnetic nanoparticles. As the cardinal features of the ideal multifunctional cancer drug nanocarrier are becoming clear, and drug development challenges are proactively addressed, we anticipate that future advances will enhance therapeutic outcomes by refining the delivery and targeting of complex payloads.

Citing Articles

Comparison of Solid Self-Nanoemulsifying Systems and Surface-Coated Microspheres: Improving Oral Bioavailability of Niclosamide.

Baek K, Woo M, Din F, Choi Y, Kang M, Kim J Int J Nanomedicine. 2024; 19:13857-13874.

PMID: 39735329 PMC: 11681811. DOI: 10.2147/IJN.S494083.


Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells.

Khaliulin M, Valiullina A, Petukhov A, Yuan Y, Spada S, Bulatov E Cancer Immunol Immunother. 2024; 74(1):3.

PMID: 39487875 PMC: 11531461. DOI: 10.1007/s00262-024-03817-z.


Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy.

Lu S, Wang C, Ma J, Wang Y Front Immunol. 2024; 15:1456030.

PMID: 39351241 PMC: 11439727. DOI: 10.3389/fimmu.2024.1456030.


Recent Advances in Targeted Therapies for Infantile Hemangiomas.

Liang T, Liu X, Tong Y, Ding Q, Yang M, Ning H Int J Nanomedicine. 2024; 19:6127-6143.

PMID: 38911507 PMC: 11193998. DOI: 10.2147/IJN.S463119.


New insights into targeted therapy of glioblastoma using smart nanoparticles.

Ghaznavi H, Afzalipour R, Khoei S, Sargazi S, Shirvalilou S, Sheervalilou R Cancer Cell Int. 2024; 24(1):160.

PMID: 38715021 PMC: 11077767. DOI: 10.1186/s12935-024-03331-3.